Literature DB >> 24166227

Empirical performance of a self-controlled cohort method: lessons for developing a risk identification and analysis system.

Patrick B Ryan1, Martijn J Schuemie, David Madigan.   

Abstract

BACKGROUND: Observational healthcare data offer the potential to enable identification of risks of medical products, but appropriate methodology has not yet been defined. The self-controlled cohort method, which compares the post-exposure outcome rate with the pre-exposure rate among an exposed cohort, has been proposed as a potential approach for risk identification but its performance has not been fully assessed.
OBJECTIVES: To evaluate the performance of the self-controlled cohort method as a tool for risk identification in observational healthcare data. RESEARCH
DESIGN: The method was applied to 399 drug-outcome scenarios (165 positive controls and 234 negative controls across 4 health outcomes of interest) in 5 real observational databases (4 administrative claims and 1 electronic health record) and in 6 simulated datasets with no effect and injected relative risks of 1.25, 1.5, 2, 4, and 10, respectively. MEASURES: Method performance was evaluated through area under ROC curve (AUC), bias, and coverage probability.
RESULTS: The self-controlled cohort design achieved strong predictive accuracy across the outcomes and databases under study, with the top-performing settings exceeding AUC >0.76 in all scenarios. However, the estimates generated were observed to be highly biased with low coverage probability.
CONCLUSIONS: If the objective for a risk identification system is one of discrimination, the self-controlled cohort method shows promise as a potential tool for risk identification. However, if a system is intended to generate effect estimates to quantify the magnitude of potential risks, the self-controlled cohort method may not be suitable, and requires substantial calibration to be properly interpreted under nominal properties.

Mesh:

Year:  2013        PMID: 24166227     DOI: 10.1007/s40264-013-0101-3

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  12 in total

1.  Determining the area under the ROC curve for a binary diagnostic test.

Authors:  S B Cantor; M W Kattan
Journal:  Med Decis Making       Date:  2000 Oct-Dec       Impact factor: 2.583

2.  Confidence limits for the ratio of two rates based on likelihood scores: non-iterative method.

Authors:  P L Graham; K Mengersen; A P Morton
Journal:  Stat Med       Date:  2003-06-30       Impact factor: 2.373

Review 3.  Role of postmarketing surveillance in contemporary medicine.

Authors:  Janet Woodcock; Rachel E Behrman; Gerald J Dal Pan
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

Review 4.  Immortal time bias in pharmaco-epidemiology.

Authors:  Samy Suissa
Journal:  Am J Epidemiol       Date:  2007-12-03       Impact factor: 4.897

5.  A comparison of the empirical performance of methods for a risk identification system.

Authors:  Patrick B Ryan; Paul E Stang; J Marc Overhage; Marc A Suchard; Abraham G Hartzema; William DuMouchel; Christian G Reich; Martijn J Schuemie; David Madigan
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

6.  Evaluating performance of risk identification methods through a large-scale simulation of observational data.

Authors:  Patrick B Ryan; Martijn J Schuemie
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

7.  Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?

Authors:  Gianluca Trifirò; Antoine Pariente; Preciosa M Coloma; Jan A Kors; Giovanni Polimeni; Ghada Miremont-Salamé; Maria Antonietta Catania; Francesco Salvo; Anaelle David; Nicholas Moore; Achille Patrizio Caputi; Miriam Sturkenboom; Mariam Molokhia; Julia Hippisley-Cox; Carlos Diaz Acedo; Johan van der Lei; Annie Fourrier-Reglat
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-12       Impact factor: 2.890

8.  Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines.

Authors:  J L Carson; B L Strom; A Duff; A Gupta; M Shaw; F E Lundin; K Das
Journal:  Ann Intern Med       Date:  1993-10-01       Impact factor: 25.391

Review 9.  Defining a reference set to support methodological research in drug safety.

Authors:  Patrick B Ryan; Martijn J Schuemie; Emily Welebob; Jon Duke; Sarah Valentine; Abraham G Hartzema
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

10.  Interpreting observational studies: why empirical calibration is needed to correct p-values.

Authors:  Martijn J Schuemie; Patrick B Ryan; William DuMouchel; Marc A Suchard; David Madigan
Journal:  Stat Med       Date:  2013-07-30       Impact factor: 2.373

View more
  16 in total

1.  How Confident Are We about Observational Findings in Healthcare: A Benchmark Study.

Authors:  Martijn J Schuemie; M Soledad Cepeda; Marc A Suchard; Jianxiao Yang; Yuxi Tian; Alejandro Schuler; Patrick B Ryan; David Madigan; George Hripcsak
Journal:  Harv Data Sci Rev       Date:  2020-01-31

2.  Replication of the OMOP experiment in Europe: evaluating methods for risk identification in electronic health record databases.

Authors:  Martijn J Schuemie; Rosa Gini; Preciosa M Coloma; Huub Straatman; Ron M C Herings; Lars Pedersen; Francesco Innocenti; Giampiero Mazzaglia; Gino Picelli; Johan van der Lei; Miriam C J M Sturkenboom
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

Review 3.  Desideratum for evidence based epidemiology.

Authors:  J Marc Overhage; Patrick B Ryan; Martijn J Schuemie; Paul E Stang
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

4.  Variation in choice of study design: findings from the Epidemiology Design Decision Inventory and Evaluation (EDDIE) survey.

Authors:  Paul E Stang; Patrick B Ryan; J Marc Overhage; Martijn J Schuemie; Abraham G Hartzema; Emily Welebob
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

5.  A comparison of the empirical performance of methods for a risk identification system.

Authors:  Patrick B Ryan; Paul E Stang; J Marc Overhage; Marc A Suchard; Abraham G Hartzema; William DuMouchel; Christian G Reich; Martijn J Schuemie; David Madigan
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

Review 6.  Electronic Health Data for Postmarket Surveillance: A Vision Not Realized.

Authors:  Thomas J Moore; Curt D Furberg
Journal:  Drug Saf       Date:  2015-07       Impact factor: 5.606

7.  Pharmacovigilance via Baseline Regularization with Large-Scale Longitudinal Observational Data.

Authors:  Zhaobin Kuang; Peggy Peissig; Vítor Santos Costa; Richard Maclin; David Page
Journal:  KDD       Date:  2017-08

8.  Empirical performance of the calibrated self-controlled cohort analysis within temporal pattern discovery: lessons for developing a risk identification and analysis system.

Authors:  G Niklas Norén; Tomas Bergvall; Patrick B Ryan; Kristina Juhlin; Martijn J Schuemie; David Madigan
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

Review 9.  Defining a reference set to support methodological research in drug safety.

Authors:  Patrick B Ryan; Martijn J Schuemie; Emily Welebob; Jon Duke; Sarah Valentine; Abraham G Hartzema
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

10.  Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest.

Authors:  Richard D Boyce; Patrick B Ryan; G Niklas Norén; Martijn J Schuemie; Christian Reich; Jon Duke; Nicholas P Tatonetti; Gianluca Trifirò; Rave Harpaz; J Marc Overhage; Abraham G Hartzema; Mark Khayter; Erica A Voss; Christophe G Lambert; Vojtech Huser; Michel Dumontier
Journal:  Drug Saf       Date:  2014-08       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.